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Abstract
Background: Sex is an important factor in the prevalence, incidence, progression, and response to treatment of many
medical conditions, including autoimmune and cardiovascular diseases and psychiatric conditions. Identification of
molecular differences between typical males and females can provide a valuable basis for exploring conditions differentially
affected by sex.
Methodology/Principal Findings: Using multiplexed immunoassays, we analyzed 174 serum molecules in 9 independent
cohorts of typical individuals, comprising 196 males and 196 females. Sex differences in analyte levels were quantified using
a meta-analysis approach and put into biological context using k-means to generate clusters of analytes with distinct
biological functions. Natural sex differences were established in these analyte groups and these were applied to illustrate
sexually dimorphic analyte expression in a cohort of 22 males and 22 females with Asperger syndrome. Reproducible sex
differences were found in the levels of 77 analytes in serum of typical controls, and these comprised clusters of molecules
enriched with distinct biological functions. Analytes involved in fatty acid oxidation/hormone regulation, immune cell
growth and activation, and cell death were found at higher levels in females, and analytes involved in immune cell
chemotaxis and other indistinct functions were higher in males. Comparison of these naturally occurring sex differences
against a cohort of people with Asperger syndrome indicated that a cluster of analytes that had functions related to fatty
acid oxidation/hormone regulation was associated with sex and the occurrence of this condition.
Conclusions/Significance: Sex-specific molecular differences were detected in serum of typical controls and these were
reproducible across independent cohorts. This study extends current knowledge of sex differences in biological functions
involved in metabolism and immune function. Deviations from typical sex differences were found in a cluster of molecules
in Asperger syndrome. These findings illustrate the importance of investigating the influence of sex on medical conditions.
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Introduction
Sexual dimorphism in underlying processes in medical condi-
tions are numerous and diverse, occurring in diseases ranging from
autoimmune and cardiovascular conditions to neurological con-
ditions [1–3]. Parameters such as disease prevalence, incidence,
age at onset, progression, mortality, and treatment response can
show sex differences [4]. The key to some of these differences may
be in sex-dependent regulation of biological pathways. Such
differences have been investigated in the context of immune
response, and elevated immune activation in females has been
linked to the significantly increased susceptibility of women to
multiple sclerosis (MS) and other autoimmune diseases such as
rheumatoid arthritis, Grave’s disease, and lupus erythematosus
[1]. Several possible avenues have been explored to explain such
differences in autoimmune diseases. For example, one study
showed that typical female mice had detectable levels of
immunoglobulin G auto-antibodies that were absent in male mice
[5]. Similarly, higher blood immunoglobulin levels and CD4/CD8
T-cell ratios have been found in typical women, along with lower
natural killer cell and antibody-dependent cell-mediated cytotox-
icity [1]. Sex dimorphic expression of particular cytokines, such as
transforming growth factor (TGF)-b1 and interleukin (IL)- 4, has
also been implicated in osteoarthritis in mice [6].
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e51504
Physiological and molecular mechanisms causing sex dimor-
phisms have also been investigated in the context of cardiovascular
diseases. Myocardial infarctions in women result in a higher
mortality rate and poorer prognosis compared to men [7]. Reports
have shown that sex differences in myocardial function appear
during physiological stress [7]. Sex differences in the stress
responses of rodent cells have been observed along with sexually
dimorphic gene expression of stress-related genes both before and
after application of stress [8]. This study showed intrinsic sex
differences in cell response to stressors such as ethanol and
influenza A virus even without exposure to sex hormones [8].
Basal hypothalamic-pituitary-adrenal (HPA) axis function was also
increased in females [9]. It has been suggested that the
reproductive and HPA axes work together with the immune
system to maintain homeostasis [9]. Stress and immune markers
are likely to show sex specific expression and response to stimuli,
potentially creating different susceptibilities to autoimmune,
cardiovascular, and other diseases in which stress and immune
responses play a role in disease vulnerability.
An increased understanding of sex dimorphisms in biological
regulation may also help to elucidate potential differences in
treatment response. For example, growth hormone, which has
been used to treat a variety of irregularities associated with
cardiovascular, immune, metabolic, psychological and other
biological functions, is less effective in women than men [10].
Sex differences in growth hormone regulation were found to be
responsible for these differences. The actions of growth hormone,
whose release is continuous in females and episodic in males, were
suppressed in cells from females [10]. This suppression has been
hypothesized to be due to suppressed signalling through cytokines
and the Jak2/Stat5B pathway that usually activates growth
hormone [10].
Studies measuring sex differences at the molecular level have so
far been limited to the investigation of only a few molecules and
specific disease and inflammation processes [1,11–14]. The aim of
the present study was to elucidate such differences at a systematic
level through measurement of 174 serum molecules in a large
cohort of typical individuals. The investigated molecules included
cytokines, chemokines, hormones, growth factors, angiogenesis
and central nervous system-related analytes, as well as other serum
proteins important in disease (Myriad RBM website. Available:
http://myriadrbm.com/. Accessed 2012 May 18). The applied
multiplexed immunoassay platform has been used previously to
explore molecular changes in cancer and autoimmune, cardiovas-
cular, gastrointestinal, neurological, and various other diseases,
many of which show sex differences [15–20]. In addition, we
attempted to relate the discovered sex differences to those
measured in samples from participants with Asperger syndrome.
This condition shows a particularly pronounced sex dimorphism
as the prevalence is 4–10-fold higher in males [21].
Materials and Methods
Clinical Samples
Protocols for the study were approved by ethical committees at
all involved university hospitals (see below) and carried out in
accordance with the Declaration of Helsinki. Informed written
consent was obtained from all participants. Individuals with a
family history of mental illness or medical conditions like
hypertension, type II diabetes, cardiovascular, or autoimmune
diseases were excluded from the study. Pregnant females were also
excluded from the study. A total of nine cohorts of typical
individuals were used in this investigation. Cohort 1 was from the
Autism Research Centre, University of Cambridge, Department of
Psychiatry, UK; cohorts 2 and 3 were from University of Cologne
Department of Psychiatry, Germany; cohorts 4 to 6 were from the
University of Muenster, Germany; cohorts 7 and 8 were from the
University of Magdeburg, Germany; and cohort 9 was from
Erasmus Medical Centre in the Netherlands. In addition, a
separate cohort of adults with Asperger syndrome (Cohort 10) was
obtained from the Autism Research Centre, University of
Cambridge, Department of Psychiatry, UK. Diagnosis of Asperger
syndrome by psychiatrists was based on the Structured Clinical
Interview for the Diagnostic and Statistic Manual-IV-Text Review
Disorders and the DSM-IV-TR. Biological sex was used to classify
males and females. Females were not excluded for contraceptive
use and were at variable times in the menstrual cycle. Blood was
collected in the morning after overnight fasting, serum prepared
and 181–247 analytes measured using multiplexed immunoassay
analyses in a CLIA-certified laboratory at Myriad-RBM (Austin,
TX, USA), as described previously [18].
Data Pre-processing
The statistical programming software R was used to match
controls, replace missing analyte values, remove outliers, and to
perform meta-analysis. For each of the nine cohorts, typical males
and females were matched according to age, BMI, waist
circumference, smoking, and cannabis consumption. Demograph-
ic details including available metadata used for matching in all
nine cohorts are shown in Table 1. Values outside the linear
range of the assay system were either replaced by half the
minimum value or by double the maximum value measured for
the respective analyte. Analytes with more than 70% missing
values were eliminated from the dataset. Outlier removal was
performed for each analyte separately and values more than four
standard deviations from the overall mean were excluded.
Meta-analysis
Meta-analysis was carried out using the non-parametric Cliff’s
delta as a measure of effect size [22–25]. Cliff’s delta estimated the
probability that the level of an analyte was higher in males than in
females versus the reverse probability. Cliff’s delta was calculated
in all cohorts to quantify the difference in molecular levels between
males and females, and the pooled effect was determined using a
random effects meta-analysis. This approach was chosen after
finding significant heterogeneity between cohorts as assessed by a
standard x2 test [26]. Random effects meta-analysis accounts for
this heterogeneity allowing cohort-specific average effects to vary
as part of a common distribution. This approach has been used
recently to detect novel loci in genome wide association studies for
various disorders [27,28]. Other uses have ranged from assessing
the effect of intentional weight loss on depressive symptoms to
examining the relationship between physical activity and risk of
colon adenoma [29,30]. For the determination of the pooled effect
size, a minimum of three cohorts was required for each analyte.
All determined p-values were adjusted for the false discovery
rate according to the method of Benjamini and Hochberg [31].
Adjusted p-values (q-values) of less than 0.05 were considered to
indicate statistical significance.
K-means Clustering and Principal Component Analysis
To assign molecules to biological pathways, we first employed a
clustering approach to group analytes with similar concentration
patterns. For this purpose, k-means clustering was performed on
standardized analyte levels measured in the largest cohort (cohort
7). To avoid the influence of outlying observations on the
clustering, such values were replaced with a uniform random
number between the minimum and maximum analyte values. The
Molecular Sex Differences
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number of clusters was pre-specified to 6, but different qualita-
tively similar results were obtained by using other cluster numbers.
The main biological functions for the analytes in each cluster of
related molecules were identified using Ingenuity Pathway Knowl-
edgebase (IPA) software with all measured molecules as the
reference dataset (Ingenuity website. Available: http://www.
ingenuity.com/. Accessed 2012 April 18). Main biological
functions were determined by identifying overrepresented func-
tions of the molecules in the cluster. These biological functions
were verified using the Database for Annotation, Visualization and
Integrated Discovery (DAVID ) version 6.7 (DAVID website.
Available: http://david.abcc.ncifcrf.gov/. Accessed 2012 Oct 16)
[32,33]. The IPA software was also used to create networks for
clustered analytes, taking into consideration direct and indirect
relationships between proteins.
The molecular clusters and their relationships to results from
the meta-analysis of sex differences were visualized using principal
component analysis (PCA; SIMCA-P+ Version 12.0). Principal
components were used to create a single composite variable
summarizing the information of all molecules in each cluster. For
this purpose, we used the first principal component of standard-
ized analyte concentrations in each cluster and determined sex
differences. These were combined across cohorts using a random
effects meta-analysis. Since principal components are indifferent
with respect to sign, this was determined using the average sign of
the individual standardized molecular concentrations within each
cluster. The average sign was calculated from the molecules with
the highest principal component loadings. Subsequently, ANOVA
was used on all principal component scores to quantify sex-by-
condition interactions in groups of analytes. P-values were
adjusted for the false discovery rate with the Benjamini and
Hochberg method [31].
Results
Meta-analysis
After data pre-processing, a pooled Cliff’s delta was calculated
for each of the 174 serum molecules across the nine cohorts of
typical individuals. Of these, a total of 77 analytes were present at
significantly different concentrations between male and female
participants after adjusting for the false discovery rate (q ,0.05,
Table 2 and 3). A positive Cliff’s delta value indicates that a
given analyte was higher in males more often, and a negative
Cliff’s delta value indicates the reverse. Table 2 shows that 40
molecules had higher concentrations in females and Table 3
shows that 37 molecules were more frequently higher in male
participants. Most data for the displayed analytes had no missing
values and all but five had less than 15% missing values.
Clusters and Molecular Sex Differences
Functional assignment of analytes was performed by clustering
molecular data from cohort 7 and determining the significantly
enriched biological functions of the molecules in each cluster
(Table 2 and 3). The full list of clustered molecules and their
assignment to the main biological function as determined by IPA
software can be found in Table S1. Apart from one, all clusters
were assigned a distinct biological function.
Molecular clusters and their relationships to sex differences
were visualized using PCA (Figure 1A). This figure reflects the
difference in molecular profiles between clusters resulting from
the applied clustering procedure. Figure 1B shows the same
plot with identified molecular sex differences determined by the
meta-analysis. The clustered groups with distinct biological
functions mainly showed consistent sex differences in analyte
levels.
We then assessed sex differences in each of the clustered
groups of analytes combined across all cohorts using a
composite value. This value summarized the sex differences
observed in a given group of molecules (Figure 2) and
mirrored the changes seen for individual analytes (Figure 1).
The cluster associated with energy production, fatty acid
metabolism, and hormone levels showed the most significant
sex differences for groups with a distinct biological function.
This included molecules such as growth hormone, sex hormone
binding globulin, trefoil factor 3, leptin, apolipoprotein AI,
Table 1. Metadata for all participants.
Cohort1
Cohort
2 Cohort3 Cohort4 Cohort5 Cohort6
Cohort
7 Cohort8 Cohort9
Cohort 10
(AS)
Controls 40 50 14 20 26 22 162 44 14 44
Controls (M/F) 20/20 25/25 7/7 10/10 13/13 11/11 81/81 22/22 7/7 22/22
Age (M) 3268 2967 3869 2467 32611 38611 37611 34611 2762 3069
Age (F) 3266 3067 3869 2467 32613 39612 37612 37612 2862 3368
Age Range (M) 19–45 19–44 29–52 18–42 20–56 20–61 19–60 19–55 25–29 19–43
Age Range (F) 20–42 21–44 28–50 18–43 20–61 20–61 18–62 21–52 25–30 18–45
BMI (M) 2362 2664 2462
BMI (F) 2264 2564 2363
WC (M) 10268 9666
WC (F) 103611 9666
Smoking (M) (Y/N/NA) 3/17/0 11/14/0 0/7/0 12/69/0 6/16/0 5/17/0
Smoking (F) (Y/N/NA) 3/17/0 12/13/0 1/6/0 17/64/0 3/19/0 5/17/0
Cannabis (M) (Y/N/NA) 0/17/3 13/11/1 0/7/0 0/81/0 0/22/0 2/14/6
Cannabis (F) (Y/N/NA) 1/14/5 14/10/1 1/5/1 0/81/0 0/22/0 0/6/16
Nine cohorts of typical individuals and one cohort of individuals with Asperger syndrome were recruited. Values are reported as mean 6 standard deviation. BMI (body
mass index, in kg/m2), WC (waist circumference, in centimetres).
doi:10.1371/journal.pone.0051504.t001
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adiponectin and thyroxine binding globulin. These all showed
higher levels in females compared to males with ratios ranging
from 1.4 to 10.0 (Table 2). The molecules which were more
abundant in males were associated mainly with immune cell
chemotaxis, although the ratiometric differences were smaller
than those observed for catabolism of fatty acids and regulation
of hormone levels in females (Table 3).
Identification of Molecular Differences in Asperger
Syndrome Associated with Sex
We next applied the sex differences identified in typical
controls to investigate the potential association of these with
Asperger syndrome. Figure 2 shows the overlay of the
naturally occurring sex differences found for each biological
function with those observed in a cohort of 44 individuals with
Asperger syndrome. Most sex differences were consistent with
those observed in typical participants, further validating the
result of the meta-analysis. However, a disease-sex interaction
approaching significance was observed for molecules associated
with fatty acid metabolism and hormone production (P=0.022;
q = 0.132) (Figure 2). This indicates that females with Asperger
syndrome showed lower levels of these molecules than would be
expected from the meta-analysis of typical controls.
Figure 3 shows the two top networks from Ingenuity
Pathway Knowledgebase software for the group of molecules
associated with fatty acid metabolism and hormone function.
Molecules are coloured according to typical sex differences and
circled where significant interactions were found for Asperger
syndrome and sex in [34]. Stem cell factor (SCF) and receptor
for advanced glycosylation end products (RAGE) in one
network, and growth hormone (GH) in the other network
showed significant sex-specific alterations in Asperger syndrome.
The software showed that these two networks, containing most
of the molecules in the cluster, were partially overlapping.
Discussion
This is the first large-scale study investigating molecular sex
differences in serum of typical individuals. The present findings
provide insight into biological pathways with specific differences in
male and female participants, significantly extending current
knowledge of sex-specific molecular profiles. These naturally
occurring differences provide a baseline for comparison against
diseases and may help to uncover pathways involved in disease-
related sex dimorphisms. A particular strength of the present study
was the multiplexed investigation of a large number of molecules
covering multiple biological pathways. This allowed a compre-
hensive assessment of changes in these pathways at the time of
sampling and circumvents problems associated with combining
results from single molecular assays across studies.
The most significant finding was a higher level of molecules
associated with oxidation of fatty acids and hormone function in
female participants. It is well known that lipid metabolism differs
between males and females, and multiple studies have suggested
that these differences are not only a consequence of phenotypical
differences such as percentage of body fat, but also related to sex
dimorphisms in metabolism itself [35]. In this context, the glycerol
rate of appearance, which has been used as an indicator of whole
body lipolytic rate, has been found to be higher in women. It has
been suggested that the associated increased release of fatty acids
can be advantageous under conditions of elevated energy demand,
but may also be related to the increased susceptibility of women to
develop fatty acid liver disease [35,36]. It is important to note that
participants analyzed in the present study were not matched for
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percentage of body fat. However, since this is a characteristic that
can be expected to differ between males and females in general, it
may be an important factor associated with disease or treatment-
related sex dimorphisms itself.
The molecules found to be associated with higher fatty acid
metabolism in females included adiponectin, leptin and apolipo-
protein AI. In contrast, molecules involved in lipid transport,
including most of the measured apolipoproteins, showed inconsis-
tent sex differences. To the best of our knowledge, this is the first
report showing different effects of sex on lipid metabolism and
transport. Elevated lipid metabolic rate coupled with few changes
in the levels of many of the apolipoproteins involved in lipid
transport in females may reflect intrinsic sex differences in the
handling of lipids, including metabolism, transport and storage.
For example, a study investigating basal, postabsorptive very low
density lipoprotein – triglyceride (VLDL-TG) kinetics identified
higher female secretion rates as well as differences in production in
clearance [35].
A second important finding was that higher levels of fatty acid
metabolism and hormone regulation-related molecules coincided
with elevated levels of immune cell chemotaxis proteins in males.
This is interesting since molecules related to immune cell growth
and activation showed the opposite behaviour and were increased
in females.
It has been established that humoral and cell-mediated immune
responses are generally more active and robust in females
compared to males and that inflammation and production of
inflammatory markers show sex differences [1,37–39]. Polymor-
phonuclear leukocytes (PMNs) in females were found to have
vigorous phagocytic responses after anaesthesia, surgery, intro-
duction of lipopolysaccharide, and acute ethanol intoxication [37].
Women also have higher amounts of serum antibodies, CD4+ T
cells and CD4/CD8 T cell ratios in blood, along with higher
cytokine expression during infection and stronger T cell humoral
immune responses [40]. The possibility that such differences could
lead to disease-related sex dimorphisms is exemplified by evidence
that dysregulation of the IL1 agonist/antagonist system may cause
greater severity of chronic fatigue syndrome [41]. Also, females
have a poorer prognosis in cases of chronic inflammatory
conditions such as cystic fibrosis and chronic pulmonary obstruc-
tive disease with greater morbidity and complications [38].
Immune reactivity has also been linked to the higher prevalence
of autoimmune diseases in females [1,41].
Recruitment of immune cells to sites of infection and
inflammation is necessary to coordinate immune response and is
important in disease, as the type of chemokine produced in a
specific condition influences inflammation [42]. Though females
generally show higher production of cytokines upon infection, we
found that analytes related to immune cell chemotaxis and cell
signalling were present at higher levels in males. These analytes
included several growth factors, monocyte chemotactic proteins
and macrophage inflammatory proteins. Lower levels of these
molecules in females are consistent with reported effects of
estrogen down-regulating chemokine production. Previous studies
have shown that estrogen treatment leads to decreased mRNA
transcription of chemoattractant proteins in macrophages and
increased production of cytokines from immature dendritic cells
[41,43]. Monocytes and macrophages also showed reduced
expression of pro-inflammatory cytokines due to the effects of
estrogen on receptor CD16 [43]. Overall, the higher levels of
many chemotactic factors found in males in this study may be due
to a lack of suppressant effects of estrogen at basal levels. This
could have important effects, especially in the initial response to
infection, autoimmunity, and diseases with links to specific
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chemokine effects. For example, autoimmune disease severity in
females has been linked to fluctuating estrogen levels and the type
of cytokine environment that they induce [40].
Differences in cytokines and inflammatory processes have also
been linked to alterations in lipid metabolism, providing further
support for the co-occurrence of such differences in the present
Figure 1. PCA plots showing individual molecules. A) Assignment of analyte clusters to biological functions; B) Sex differences as determined
by meta-analysis. Colouring indicates significance (q,0.05). The grey area indicates analytes that show no significant sex differences. Plots were
generated using data from cohort 7, in which 167 analytes were measured in 162 typical controls (81 females, 81 males).
doi:10.1371/journal.pone.0051504.g001
Figure 2. Sex differences of composite variables summarizing analyte clusters. Values for typical individuals were pooled across nine
cohorts; values for Asperger syndrome participants were calculated from cohort 10. The x-axis shows the difference between composite values that
reflect the average molecular levels in males and females. Horizontal bars indicate 95% confidence intervals of the difference between sexes.
doi:10.1371/journal.pone.0051504.g002
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study. Adiponectin has been found previously to be elevated in
females and this sex difference decreased linearly with the stage of
diabetes progression. The inflammatory molecules C-reactive
protein (CRP) and IL1 receptor antagonist (RA) were also
increased in pre-diabetic and diabetic women, and these increased
even further as the disease progressed, relative to the findings in
males [44]. Adiponectin has also been found to decrease
endothelial cell CRP synthesis and secretion [45]. Adiponectin
and CRP were both found to be present at higher concentrations
in females in our study, and were associated with the fatty acid
metabolism analyte cluster. Such links between lipid metabolism
and inflammatory markers have interesting implications in sex
dimorphisms in metabolic syndrome, cardiovascular disease and
other related disorders [46].
To evaluate sex dimorphisms deviating from the variation seen
in normal controls, we investigated a cohort of participants with
Asperger syndrome, which is characterised by a particularly
pronounced sex difference in incidence. This analysis led to
identification of an interaction in a clustered group of molecules
enriched in fatty acid catabolism and hormone regulation
functions, indicating a deviation from normal sex variation that
affected an entire system of molecules. Interactions for individual
molecules within the cluster have previously been shown in
Asperger syndrome in [34]. Investigation into other molecules part
of the detected networks, which have not been associated with
Asperger syndrome as yet, has potential to help explain the sex-
specific effects in this cluster of molecules and its biological
implications for this condition. It is worthwhile to note that the
cytokine alterations that were previously observed at the individual
analyte level in the same cohort were not apparent at the pathway
level [34]. This may be due to the separation of inflammatory
molecules into multiple distinct sets combined with a lack of
change seen in other related molecules in the cluster. These results
indicate the importance of this set of related molecules, associated
most strongly with fatty acid oxidation and hormone function, in
the molecular basis of Asperger syndrome. This is particularly
Figure 3. Sex-specific effects in networks for Asperger syndrome. Top networks of the cluster of molecules associated with energy
production, fatty acid metabolism, and hormone levels from Ingenuity Pathway Knowledgebase software. Individual molecules are coloured
according to significant sex difference in controls. Molecules with significant sex-disease interactions from [34] are circled. A2M (alpha 2
macroglobulin), ADIPOQ (adiponectin), RAGE (receptor for advanced glycosylation end products), ANGPT2 (angiopoietin 2), ARNT (aryl hydrocarbon
receptor nuclear translocator), CRP (C-reactive protein), ENA-78 (epithelial derived neutrophil activating protein 78), EDNRB (endothelin receptor type
B), EPO (erythropoietin), ERK (extracellular-signal-regulated kinase), FCER1A (Fc fragment of IgE, high affinity I, receptor for alpha polypeptide), GAB1
(GRB2-associated binding protein 1), GCLC (glutamate-cysteine ligase, catalytic subunit), IL17F (interleukin-17F), Jnk (c-Jun N-terminal kinase), SCF
(stem cell factor), LEP (leptin), LHB (luteinizing hormone beta polypeptide), Mapk (mitogen-activated protein kinase), NFkB (complex) (nuclear factor
of kappa light polypeptide gene enhancer in B-cells), NOX3 (NADPH oxidase 3), P38 MAPK (P38 mitogen-activated protein kinase), PRKAA1 (protein
kinase, AMP-activated, alpha 1 catalytic subunit), PRKAA2 (protein kinase, AMP-activated, alpha 2 catalytic subunit), PSMD4 (proteasome (prosome,
macropain) 26S subunit, non-ATPase, 4), SMPD2 (sphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)), TFF3 (trefoil
factor 3), AGT (angiotensinogen), APOA1 (apolipoprotein AI), COL18A1 (collagen, type XVIII, alpha 1), CXCL11 (chemokine (C-X-C motif) ligand 11),
BLC (B lymphocyte chemoattractant), MIG (monokine induced by gamma interferon), Fcgr2 (Fc gamma R2), FDX1 (ferredoxin 1), FDXR (ferredoxin
reductase), FSH (follicle stimulation hormone), GCLC (glutamate-cysteine ligase, catalytic subunit), GH (growth hormone), GHR (growth hormone
receptor), SGOT (serum glutamic oxaloacetic transaminase), KIM-1 (kidney injury molecule 1), HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3
beta- and steroid delta-isomerase 2), IL6 (interleukin-6), ITK (IL2-inducible T-cell kinase), LDLR (low density lipoprotein receptor), LPL (lipoprotein
lipase), LSS (lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)), MSMO1 (methylsterol monooxygenase 1), NLRP12 (NLR family, pyrin domain
containing 12), NPPB (brain natriuretic peptide), NR1H4 (nuclear receptor subfamily 1, group H, member 4), OSMR (oncostatin M receptor), PI3K
(complex) (phosphoinositide-3-kinase), SCARB1 (scavenger receptor class B, member 1), TBG (thyroxine binding globulin), SST (somatostatin), Stat5a/
b (signal transducer and activator of transcription a/b), TCR (T-cell receptor), TNF-alpha (tumor necrosis factor-alpha), TNFRSF11B (tumor necrosis
factor receptor superfamily, member 11b), VWF (von Willebrand factor).
doi:10.1371/journal.pone.0051504.g003
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interesting since Asperger syndrome has been associated with
higher free testosterone levels in female participants and testos-
terone is known to be a strong regulator of lipid metabolism [47–
49].
Conclusions
In summary, we have established that important sex differences
exist in human serum using a multiplex immunoassay system.
Specifically, we found sex differences in molecules related to
metabolism and immune cell function, which may be explored
more deeply in the context of disorders associated with sex effects.
We have also shown that a cluster of molecules associated with
fatty acid metabolism and hormone levels exhibits sex dimorphic
differences in a cohort of adults with Asperger syndrome. Such
differences indicate that Asperger syndrome, and potentially other
autism spectrum conditions, may develop differently in males and
females according to sex-specific molecular pathways [21,50].
These findings suggest that there is considerable scope for further
studies of the effect of sex on disease susceptibility and
development.
Supporting Information
Table S1 Clusters of molecules. Assignment of all molecules in
cohort 7 using k-means clustering.
(XLSX)
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